BioCentury
ARTICLE | Emerging Company Profile

Asher Bio: aiming cytokine therapies at specific immune cells

Emerging Company Profile: Asher Bio engineering cytokine specificity with Third Rock-led $55 million series A

March 25, 2021 11:06 PM UTC

Asher Bio emerged from stealth Tuesday with a $55 million series A led by Third Rock and a platform to improve the safety and efficacy of cytokine therapies for cancer. 

Boxer Capital, Invus and seed investors Y Combinator and MBC Biolabs also participated in Asher Biotherapeutics Inc.’s A round...

BCIQ Company Profiles

Asher Biotherapeutics Inc.

BCIQ Target Profiles

Interleukin-2 (IL-2)